H.C. Wainwright lowered the firm’s price target on Invivyd (IVVD) to $10 from $15 and keeps a Buy rating on the shares following the Q3 report. The firm expects expect the launch of Pemgarda, which is off to a slower than expected start, to accelerate in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD: